Division of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Clin Ther. 2021 Mar;43(3):549-556. doi: 10.1016/j.clinthera.2021.01.014. Epub 2021 Jan 22.
In December 2020, the US Food and Drug Administration issued emergency use authorizations for two mRNA vaccines against coronavirus disease 2019. These vaccines represent an incredible scientific achievement and a major step in efforts to bring the global pandemic to a close. However, these vaccines create many logistical challenges that limit just how far-reaching their impact can be. This commentary reviews how these vaccines offer immunity, summarizes the Phase III trial results, and offers a discussion of the challenges that remain after these vaccines are introduced for widespread use.
2020 年 12 月,美国食品和药物管理局发布了两项针对 2019 年冠状病毒病的 mRNA 疫苗的紧急使用授权。这些疫苗代表了一项令人难以置信的科学成就,也是努力结束全球大流行的重要一步。然而,这些疫苗带来了许多后勤方面的挑战,限制了其影响的广泛程度。本评论回顾了这些疫苗如何提供免疫力,总结了 III 期临床试验结果,并讨论了这些疫苗广泛使用后面临的挑战。